Empowering New Zealand Nurses for Excellence in Healthcare

Pharmac has decided to fund a new medicine for people in hospital with serious infections and to improve access to medicines for difficult-to-treat bacterial infections and high blood pressure.From 1 November 2026, Pharmac will: Fund ceftolozane with tazobactam for people with serious multidrug-resistant bacterial infections. Widen access to bedaquiline and linezolid for people with non-tuberculous mycobacterial infections. Widen access to captopril oral liquid for people with spinal cord...

This systematic review and network meta-analysis evaluated the benefits and harms of add‑on oral antihistamines for atopic dermatitis (eczema).1 Forty‑seven randomised trials (6230 participants) assessed H1 antihistamines, H2 blockers, mast cell stabilisers, or combinations. With moderate certainty, first‑ and second‑generation H1 antihistamines produced small reductions in eczema severity (mean difference −1.87) and itch (mean difference−0.89), far below the minimal important differences....

Flamazine cream discontinuation The supplier, Smith & Nephew, will stop supplying Flamazine cream (Pharmacode: 2343851) sulfadiazine silver 1% to the New Zealand market. Stock is expected to run out in December 2026/January 2027. Flamazine cream discontinuation Glibenclamide (Daonil) tab 5 mg discontinuation The supplier, Sanofi, is discontinuing Daonil (glibenclamide) tab 5 mg globally. Stock is expected to run out in February 2027. Glibenclamide (Daonil) tab 5 mg discontinuation Updated...

Please see below updates from Pharmac. Supply issue Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml Brand change Cetirizine hydrochloride oral liquid 1mg/ml 1.Supply Issue update: Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml An alternate product was funded from August - Teriparatide S29 20 micrograms/80 microlitres, solution for Injection Pre-filled Pen 2.4 ml This UK-branded teriparatide has now received approval from Medsafe. It can be prescribed...

Please see below updates from Pharmac. Supply issue Sildenafil (Vedafil) 50mg tablets. Hydrocortisone acetate (Colifoam) rectal foam 10% Venlafaxine 75 mg capsules (Enlafax XR) Brand change Dimethicone cream 10% pump bottle Discontinuation Daonil (glibenclamide) tab 5 mg Flamazine (silver sulfadiazine cream 1%) 1.Supply Issue: Sildenafil (Vedafil) 50mg tablets There is a supply issue affecting sildenafil (Vedafil) 50mg tablets. Pharmac previously funded a Section 29 alternate brand,...

We have opportunities available to provide weekly rounds to an Aged Residential Care (ARC) facility in a Central Auckland suburb. Add variety to your week with regular round in ARC facilities. Rounds can work alongside your existing role providing a refreshing addition to traditional clinic work. Build meaningful relationships with older adults, enjoy a supportive team and dedicated recruitment support. Dedicated recruitment support. NP opportunities also available nationwide. Seeking...

New supply notices Colifoam (hydrocortisone acetate rectal foam) Colifoam (Pharmacode: 2611120) may go out of stock during October 2026. Two alternative products are funded from 8 October. Details are on the website. Colifoam (hydrocortisone acetate rectal foam) Venlafaxine (Enlafax XR) 75 mg capsule The supplier expects to run out this product (Pharmacode: 2713411) by mid-October. We have funded an alternative from 8 October. Details are on the website. Venlafaxine (Enlafax XR) 75 mg...

Our latest CPD options for you: Opioid substitution treatment There have been significant developments in OST provision in primary care and community pharmacies. These two short courses provide guidance and updated clinical advice: Opioid substitution treatment in primary care: For clinicians authorised to prescribe OST for specific clients under a specialist OST service. Opioid substitution treatment services in community pharmacies: Operational aspects of providing OST, methadone and...

Looking for a role that combines professional satisfaction with an incredible lifestyle? At Taupō Health Centre, we are proud to provide high-quality, equitable healthcare to our community – and we would love you to join us. Our clinic is a busy General Practice with an on-site Urgent Care Clinic, caring for approximately for 11,000 enrolled patients, as well as providing care for casual patients. We also provide after-hours support on Saturdays and Public Holidays on a rostered basis in...

Nurse Practitioner Primary Care—Make an Impact, Without Giving Up Balance Bring your expertise to a trusted general practice where you’ll have the autonomy to lead care, the support to thrive and the time to enjoy life beyond work. Are you an experienced Nurse Practitioner looking for a role where your judgement is trusted, your ideas are welcomed and your work creates a lasting difference? This is your opportunity to practise at the top of your scope in a team that genuinely values what...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 2 October 2026. It includes information on: Reminders Resolved Supply Issues Discontinuation Reminder: Sodium valproate (Epilim) 100mg crushable tablets Sanofi expects that stock will be available until the end of November 2026. Please transition affected patients as soon as possible. For more information Epilim discontinuation on Pharmac website Coversyl tablets...

Collaborative and impactful role New Zealand Nurse Practitioner contributing to the School’s registered Nurse Prescriber and Nurse Practitioner programmes Great Team Environment Part-time (0.6FTE), permanent position working at AUTs North Campus (Akoranga) Auckland University of Technology (AUT) is New Zealand's newest university and one of its most distinctive. Centred on students and grounded in knowledge that works, AUT is 5-star rated by QS, with more than 27,000 students and 4,000...

Competitive remuneration, professional autonomy and more control over how you work. Waiuku Health Centre is looking for a Nurse Practitioner to join our collegial primary care team in Waiuku, South Auckland. We offer full-time or part-time hours, with flexibility and genuine input into how your working week is structured. This is an opportunity to practise at the top of your scope, enjoy meaningful community healthcare and maintain a sustainable work–life balance. Remuneration:...

Director: Nurse Practitioners New Zealand Shape the future of Nurse Practitioner leadership in Aotearoa Part-time (0.6 FTE) | Permanent | Remote within Aotearoa New Zealand Ehara taku toa i te toa takitahi Engari, he toa takitini My successes are not mine alone, they are ours, the greatest successes we will have are from working together Nurse Practitioners are transforming healthcare delivery across Aotearoa. As access, equity, and workforce challenges continue to evolve, there has...

Please see below updates from Pharmac. Funding changes Widening of Access: Rosuvastatin removal of Special Authority Reminder of Coversyl change of salt Perindopril erbumine to Perindopril arginine Reminder of discontinuation Epilim tab 100mg crushable 1. Widening of Access: Rosuvastatin removal of Special Authority From 1 October 2026, rosuvastatin no longer requires a Special Authority for patients to receive funded access. This means it is open listed and may be prescribed funded...

Contents Expanding Extended Pharmacy Services New supply notices Updated supply notices Consultations and notifications Monthly updates Decision to expand Extended Pharmacy Services (EPS) From 1 October 2026 the range of funded medicines community pharmacies can provide directly to people in their communities will be expanded further to include: Treatments for children with mild dermatitis Treatments for children with bacterial and fungal skin infections Treatments for children with oral...

The U.S. hypertension guideline updates screening, treatment thresholds, and condition-specific management.1 Screening for primary aldosteronism is now recommended for all cases of resistant hypertension, and most antihypertensives (except MRAs) should be continued during testing. Potassium-based salt substitutes may help lower BP except in CKD or impaired potassium excretion. Medication with treatment recommended at ≥130/80 mm Hg for higher-risk groups and after lifestyle trials for...

Please find below, link to published CDNM Media Release: 10 Sep - CDNM Celebrates Research Excellence and Indigenous Leadership

Please find below, link to CDNM Media Release: 9 Sep - CDNM (NZ) - Maintaining Nursing Expertise and Māori Representation Critical to Public Safety